Background illustration for clinical trials search

Chronic Lymphocytic Leukemia Clinical Trials

Browse 1,537 chronic lymphocytic leukemia clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

for
Chronic Lymphocytic Leukemia (CLL),
Location: Bethesda MD
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Sex: All

Age: 18 - 70+

Code: NCT07428707

Early Phase 1, Recruiting
Active & ResponsiveNew

Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Columbus OH
Sponsor: Jennifer Woyach

Sex: All

Age: 18+

Code: NCT07557056

Phase 2, Recruiting
Active & Responsive

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

for
Chronic Lymphocytic Leukemia
Location: Portland OR
Sponsor: OHSU Knight Cancer Institute

Sex: All

Age: 18+

Code: NCT05943496

Phase 1, Recruiting
Active & Responsive

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

for
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL),
Location: Cincinnati OH, Grand Rapids MI, Chicago IL, St Louis MO,
Sponsor: Umoja Biopharma

Sex: All

Age: 18+

Code: NCT06528301

Phase 1, Recruiting
Active & Responsive

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

for
Recurrent Transformed Chronic Lymphocytic Leukemia,
Location: New York NY, Columbus OH, Salt Lake City UT
Sponsor: Aseel Alsouqi

Sex: All

Age: 18+

Code: NCT05873712

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

for
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia,
Location: Boston MA, Atlanta GA, Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18 - 70+

Code: NCT06059391

Phase 2, Recruiting
Active & Responsive

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

for
Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive,
Location: Boston MA, Atlanta GA, Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18 - 70+

Code: NCT07020533

Phase 1, Recruiting
Active & Responsive

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

for
Chronic Lymphocytic Leukemia, B-cell Malignancies
Location: Florham Park NJ, Miami Beach FL, Pittsburgh PA,
Sponsor: Curis, Inc.

Sex: All

Age: 18+

Code: NCT07271667

Phase 2, Recruiting
Active & Responsive

Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Columbus OH
Sponsor: Kerry Rogers

Sex: All

Age: 18+

Code: NCT07734038

Phase 2, Recruiting
Active & Responsive

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

for
Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV,
Location: Halifax, Montreal, Toronto, Calgary
Sponsor: AstraZeneca

Sex: All

Age: 18

Code: NCT07509151

Phase 3, Recruiting
Active & Responsive

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

for
CLL / SLL, CLL (Chronic Lymphocytic Leukemia),
Location: Chapel Hill NC, Columbus OH, Cincinnati OH,
Sponsor: Lomond Therapeutics Holdings, Inc.

Sex: All

Age: 18+

Code: NCT06708897

Phase 1, Recruiting
Active & Responsive

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

for
Recurrent Acute Lymphoblastic Leukemia,
Location: Columbus OH
Sponsor: Sumithira Vasu

Sex: All

Age: 2+

Code: NCT05418088

Phase 1, Recruiting
Active & Responsive

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

for
CLL/SLL
Location: Boston MA, Charlotte NC, Jacksonville FL, Canton OH,
Sponsor: Ascentage Pharma Group Inc.

Sex: All

Age: 18 - 70+

Code: NCT04215809

Phase 1, Recruiting
Active & Responsive

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

for
Multiple Myeloma in Relapse, Myeloma Multiple,
Location: Boston MA, Hackensack NJ, Tampa FL, Atlanta GA,
Sponsor: Kelonia Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07075185

Phase 1, Recruiting
Active & Responsive

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

for
Cancer, Breast Cancer, Lung Cancer, Colon Cancer,
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT03702309

Recruiting
Active & Responsive

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

for
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver,
Location: Scarborough ME, Worcester MA, Hartford CT, Norwalk CT,
Sponsor: Massive Bio, Inc.

Sex: All

Age: 0+

Code: NCT03452774

Recruiting
Active & Responsive

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

for
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma,
Location: Boston MA, New York NY, Fairfax VA, Durham NC,
Sponsor: Alterome Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06835569

Phase 1, Recruiting
Active & Responsive

F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors)

for
Oral Mucositis, Periodontal Diseases, Cancer
Location: Washington D.C. DC
Sponsor: Georgetown University

Sex: All

Age: 25 - 70+

Code: NCT06315855

Recruiting
Active & Responsive

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

for
Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung,
Location: New York NY, Jacksonville FL, Tampa FL, Columbus OH,
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT06682793

Phase 1, Phase 2, Recruiting
Active & Responsive

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for
PIK3CA Mutation, Solid Tumor, Adult,
Location: Boston MA, New Haven CT, New York NY, New Brunswick NJ,
Sponsor: Relay Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05216432

Phase 1, Recruiting

What is chronic lymphocytic leukemia?

Chronic lymphocytic leukemia, or CLL, is a slow growing cancer of B lymphocytes that build up in the blood, bone marrow, and lymph nodes. Most people are diagnosed around age 70, often with no symptoms; when symptoms come, they include tiredness, swollen lymph nodes, frequent infections, night sweats, and weight loss. Small lymphocytic lymphoma is the same disease when the cells sit mainly in lymph nodes, so it is studied in the same trials.

When treatment is needed, it is now mostly targeted pills: BTK inhibitors taken continuously, or venetoclax based combinations taken for a fixed time. CAR T cell therapy was approved for CLL in 2024 for people whose disease has stopped responding to both. Genetic features such as TP53 mutation, deletion 17p, and IGHV status strongly predict how CLL behaves and which trials fit. Other leukemias are on our leukemia clinical trials page.

Types of CLL clinical trials

Who can participate in CLL clinical trials?

How CLL is staged, and why it matters for trials

How to enroll in a CLL clinical trial